Bayer Pharma AG / MorphoSys AG / Antibody Targeting Wnt Pathway MorphoSys AG / OncoMed Pharmaceuticals / Frankfurt Stock Exchange / /
Country
Germany / United States / / /
Event
Company Listing Change / Business Partnership / /
IndustryTerm
pharmaceutical industry / treatment of cancer / library technology / human healthcare / pharmaceutical partners / healthcare products / diagnostic applications / published online data / /
MedicalCondition
tumor / Alzheimer’s disease / cancer / advanced solid tumors / rheumatoid arthritis / human tumors / preclinical human tumor / /
Organization
National Academy of Sciences / / /
Position
Claudia Gutjahr-Löser Head of Corporate Communications / leader / Manager Corporate Communications & IR Tel / Jessica Kulpi Specialist Corporate Communications / /
Product
HuCAL / /
PublishedMedium
Proceedings of the National Academy of Sciences / /
Technology
pharmacokinetics / library technology / antibodies / drug development / /
Media Release Martinsried/Munich, Germany, July 5, 2012 MorphoSys Partner OncoMed Publishes Data on HuCAL Antibody OMP-18R5 Preclinical Data Published in PNAS Demonstrates Potent Anti-Cancer Activity of